Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Adage Capital Partners GP, L.L.C.

SEC CIK
0001165408
Latest filing
Aug 14, 2026

The latest 13F from Adage Capital Partners GP, L.L.C. covers Q2 2026 (filed Aug 14, 2026): 1,002 long positions worth $71.3B. The top 10 holdings make up 29.5% of the portfolio, and the largest is NVIDIA Corp (NVDA) at 6.2%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Full comparison

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

New
175
Est. +$2.94B
Added
290
Est. +$5.45B
Reduced
391
Est. −$8.33B
Sold out
127
Est. −$2.74B

Top 5 holdings

Share of this quarter's portfolio value

  1. NVDANVIDIA Corp
    6.2%$4.39BHistory
  2. AAPLApple Inc.
    5.3%$3.76BHistory
  3. MSFTMicrosoft Corp
    3.4%$2.45BHistory
  4. AMZNAmazon Com Inc
    2.9%$2.09BHistory
  5. GOOGLAlphabet Inc.
    2.6%$1.86BHistory

Share of portfolio

Top 5 holdings and the other 997 positions, by share of portfolio value

  1. NVDA6.2%
  2. AAPL5.3%
  3. MSFT3.4%
  4. AMZN2.9%
  5. GOOGL2.6%
  6. Other 997 positions79.6%

Biggest buys

New and added positions, by estimated amount bought

  1. DVNDevon Energy Corp
    +$314.3MAddedHistory
  2. MRVLMarvell Technology, Inc.
    +$222.2MNewHistory
  3. SYRESpyre Therapeutics, Inc.
    +$152.9MNewHistory
  4. UALUnited Airlines Holdings, Inc.
    +$133.8MAddedHistory
  5. BBIOBridgeBio Pharma, Inc.
    +$123.1MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. AMDAdvanced Micro Devices Inc
    +0.76 pp0.4% → 1.2%History
  2. DVNDevon Energy Corp
    +0.42 pp0.1% → 0.5%History
  3. LRCXLam Research Corp
    +0.34 pp0.4% → 0.7%History
  4. MRVLMarvell Technology, Inc.
    +0.31 pp0.0% → 0.3%History
  5. GOOGAlphabet Inc.
    +0.27 pp1.8% → 2.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. RVMDRevolution Medicines, Inc.
    −$913.6MReducedHistory
  2. CNTACentessa Pharmaceuticals plc
    −$354.5MSold outHistory
  3. CTRACoterra Energy Inc.
    −$288.8MSold outHistory
  4. RPRXRoyalty Pharma plc
    −$279.3MReducedHistory
  5. LLYEli Lilly & Co
    −$276.6MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. RVMDRevolution Medicines, Inc.
    −0.67 pp0.8% → 0.2%History
  2. CNTACentessa Pharmaceuticals plc
    −0.55 pp0.5% → 0.0%History
  3. CTRACoterra Energy Inc.
    −0.45 pp0.4% → 0.0%History
  4. CVXChevron Corp
    −0.40 pp0.8% → 0.4%History
  5. RPRXRoyalty Pharma plc
    −0.36 pp0.6% → 0.2%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$71.3B
+$6.52B (+10.1%) vs. prior quarter
Positions
1,002
+48 vs. prior quarter
Top 10 concentration
29.5%
Top 10 as share of value
Turnover
12.3%
Q2 2026, one quarter
Average holding period
16.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $71.3B (Q2 2026)

Q1 2021: $49.0BQ2 2021: $51.1BQ3 2021: $50.8BQ4 2021: $55.5BQ1 2022: $52.7BQ2 2022: $43.6BQ3 2022: $40.3BQ4 2022: $41.8BQ1 2023: $44.6BQ2 2023: $46.0BQ3 2023: $44.1BQ4 2023: $48.3BQ1 2024: $52.9BQ2 2024: $54.0BQ3 2024: $56.6BQ4 2024: $57.2BQ1 2025: $54.0BQ2 2025: $59.3BQ3 2025: $63.1BQ4 2025: $66.1BQ1 2026: $64.8BQ2 2026: $71.3B
Q1 2021Q2 2026
13F filings of Adage Capital Partners GP, L.L.C. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20261,002$71.3BNVDAAAPLMSFTvs. Q1 2026SEC
Q1 2026May 15, 2026954$64.8BNVDAAAPLMSFTvs. Q4 2025SEC
Q4 2025Feb 17, 2026904$66.1BNVDAAAPLMSFTvs. Q3 2025SEC
Q3 2025Nov 14, 2025872$63.1BNVDAMSFTAAPLvs. Q2 2025SEC
Q2 2025Aug 14, 2025843$59.3BNVDAMSFTAAPLvs. Q1 2025SEC
Q1 2025May 15, 2025836$54.0BAAPLMSFTNVDAvs. Q4 2024SEC
Q4 2024Feb 14, 2025869$57.2BAAPLNVDAMSFTvs. Q3 2024SEC
Q3 2024Nov 14, 2024864$56.6BAAPLMSFTNVDAvs. Q2 2024SEC
Q2 2024Aug 14, 2024860$54.0BMSFTNVDAAAPLvs. Q1 2024SEC
Q1 2024May 15, 2024861$52.9BMSFTAAPLNVDAvs. Q4 2023SEC
Q4 2023Feb 14, 2024842$48.3BMSFTAAPLAMZNvs. Q3 2023SEC
Q3 2023Nov 14, 2023859$44.1BAAPLMSFTAMZNvs. Q2 2023SEC
Q2 2023Aug 14, 2023862$46.0BAAPLMSFTAMZNvs. Q1 2023SEC
Q1 2023May 15, 2023913$44.6BAAPLMSFTAMZNvs. Q4 2022SEC
Q4 2022Feb 14, 2023973$41.8BAAPLMSFTAMZNvs. Q3 2022SEC
Q3 2022Nov 14, 20221,047$40.3BAAPLMSFTAMZNvs. Q2 2022SEC
Q2 2022Aug 15, 20221,075$43.6BAAPLMSFTAMZNvs. Q1 2022SEC
Q1 2022May 16, 20221,080$52.7BAAPLMSFTAMZNvs. Q4 2021SEC
Q4 2021Feb 14, 20221,018$55.5BAAPLMSFTAMZNvs. Q3 2021SEC
Q3 2021Nov 15, 20211,015$50.8BAAPLMSFTAMZNvs. Q2 2021SEC
Q2 2021Aug 16, 20211,010$51.1BAAPLMSFTAMZNvs. Q1 2021SEC
Q1 2021May 17, 2021951$49.0BAAPLMSFTAMZN–SEC

13D and 13G filings

Companies where Adage Capital Partners GP, L.L.C. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

4 companies, largest stake first.

Companies where Adage Capital Partners GP, L.L.C. owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
STTKShattuck Labs, Inc.13G/A9.79%4.67M shares–Jan 29, 20242 filingsFeb 12, 2025SEC
TCRXTScan Therapeutics, Inc.13G/A7.13%3.50M shares–Jun 12, 20233 filingsFeb 12, 2025SEC
SLNOSoleno Therapeutics Inc13G/A6.44%2.78M shares–Oct 12, 20233 filingsFeb 12, 2025SEC
MREOMereo BioPharma Group plc13G/A5.62%43.6M shares–Feb 5, 20242 filingsFeb 12, 2025SEC

Latest filings

462 filings on file made by Adage Capital Partners GP, L.L.C. or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Adage Capital Partners GP, L.L.C.
CompanyFiled (ET)FormStakeChangeEvent dateFiling
VERUVeru Inc.Feb 12, 20259:43 AM ET13G/A1.57%2.30M shares–Below 5%Dec 31, 2024SEC
SOCSable Offshore Corp.Feb 12, 20259:42 AM ET13G/A3.59%3.20M shares–Below 5%Dec 31, 2024SEC
SYRSSyros Pharmaceuticals, Inc.Feb 12, 20259:41 AM ET13G/A1.98%531.9K shares–Below 5%Dec 31, 2024SEC
NKTXNkarta, Inc.Feb 12, 20259:40 AM ET13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
CMPXCompass Therapeutics, Inc.Feb 12, 20259:39 AM ET13G/A4.36%5.99M shares–Below 5%Dec 31, 2024SEC
TCRXTScan Therapeutics, Inc.Feb 12, 20259:38 AM ET13G/A7.13%3.50M shares–Dec 31, 2024SEC
MREOMereo BioPharma Group plcFeb 12, 20259:34 AM ET13G/A5.62%43.6M shares–Dec 31, 2024SEC
SLNOSoleno Therapeutics IncFeb 12, 20259:34 AM ET13G/A6.44%2.78M shares–Dec 31, 2024SEC
STTKShattuck Labs, Inc.Feb 12, 20259:33 AM ET13G/A9.79%4.67M shares–Dec 31, 2024SEC
BNTCBenitec Biopharma Inc.Apr 11, 202413G/AOld format–––SEC
KALVKalVista Pharmaceuticals, Inc.Feb 26, 202413GOld format–New–SEC
SOCSable Offshore Corp.Feb 26, 202413GOld format–New–SEC
BBOTBridgeBio Oncology Therapeutics, Inc.Feb 23, 202413GOld format–New–SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.Feb 12, 202413GOld format–New–SEC
SLDBSolid Biosciences Inc.Feb 7, 202413GOld format–New–SEC
PICCPivotal Investment Corp IIIFeb 7, 202413G/AOld format–––SEC
BlueRiver Acquisition Corp.Feb 7, 202413G/AOld format–––SEC
IVCBInvest Acquisition CorpFeb 7, 202413G/AOld format–––SEC
PGSSPegasus Digital Mobility Acquisition Corp.Feb 7, 202413G/AOld format–––SEC
SKGRUSK Growth Opportunities CorpFeb 7, 202413G/AOld format–––SEC